Abstract
Fibrinolytic enzymes are agents that dissolve fibrin clots. These fibrinolytic agents have potential use to treat cardiovascular diseases, such as heart attack and stroke. In the present article, a fibrinolytic enzyme producing Pseudoalteromonas sp. IND11 was isolated from the fish scales and optimized for enzyme production. Cow dung was used as a substrate for the production of fibrinolytic enzyme in solid-state culture. A two-level full factorial design was used for the screening of key ingredients while further optimization was carried out using the central composite design. Statistical analysis revealed that the second-order model is significant with model F-value of 6.88 and R2 value of 0.860. Enzyme production was found to be high at pH 7.0, and the supplementation of 1% (w/w) maltose and 0.1% (w/w) sodium dihydrogen phosphate enhanced fibrinolytic enzyme production. The optimization of process parameters using response surface methodology resulted in a three-fold increase in the yield of fibrinolytic enzyme. This is the first report on production of fibrinolytic enzyme using cow dung substrate in solid-state fermentation.
Highlights
Fibrin is the main component of the blood clot, and it is normally formed from fibrinogen by the action of thrombin (EC. 3. 4. 21. 5)
This is the first report on production of fibrinolytic enzyme using cow dung substrate in solid-state fermentation
It is believed that sea water, which is saline in nature and chemically closer to the human blood plasma, could provide biomolecules, in particular enzymes that could have lower or no toxicity or side effects when used for therapeutic applications (Sabu 2003)
Summary
Fibrin is the main component of the blood clot, and it is normally formed from fibrinogen by the action of thrombin (EC. 3. 4. 21. 5). Fibrin is the main component of the blood clot, and it is normally formed from fibrinogen by the action of thrombin The accumulation of fibrin in the blood vessels usually results in thrombosis. Thrombus in blood vessels or in a chamber of the heart leads to myocardial infarction and other cardiovascular diseases (CVDs). For thrombolytic therapies, both injection and oral administration of thrombolytic agents have been extensively investigated. Both injection and oral administration of thrombolytic agents have been extensively investigated Based upon their mechanism of activation of the fibrinolytic system, fibrinolytic agents are classified into two types. One is plasminogen activator such as tissue-type plasminogen activator (t-PA) (Collen and Lijnen 2004) and urokinase (Duffy 2002).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
